Support and Savings Make Onboarding Patients Easy
Savings Card and comprehensive coverage
Eligible patients pay as little as $35 for a 30-day prescription fill. Terms and Conditions Apply.
With the COMBIVENT RESPIMAT Savings Card, eligible patients pay as little as $35 for a 30-day prescription fill. Terms and Conditions Apply.
Patients may enroll in the Savings Card Program through the patient website at combivent.com or receive a card through CareConnect4Me, the COMBIVENT RESPIMAT information resource, by calling 1-877-264-2440 Monday through Friday, 8 AM to 8 PM ET.
Breathe easy with access and affordability.
95% of COMBIVENT RESPIMAT prescriptions are covered as of 2023*
*Includes aggregate of commercial and Medicaid prescriptions.
Patient Education
Starting and staying on treatment has never been easier with educational and motivational support available to your patients.
How to use RESPIMAT inhaler
The step-by-step video shows patients how to prepare the RESPIMAT inhaler and use it every day.
Quick Start Guide
COMBIVENT RESPIMAT Treatment Tracker
Tips for COPD Treatment
Time-tested, healthcare professional–trusted
Discover how COMBIVENT RESPIMAT has delivered relief and support over the decades.
The COMBIVENT RESPIMAT inhaler difference
Learn how the soft mist is delivered with ease.
Reference
- Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
COMBIVENT RESPIMAT is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
COMBIVENT RESPIMAT is contraindicated in patients hypersensitive to any of the ingredients of the drug product or to atropine or its derivatives.
COMBIVENT RESPIMAT can produce paradoxical bronchospasm that can be life-threatening. If it occurs, therapy with COMBIVENT RESPIMAT should be discontinued immediately and alternative therapy instituted.
The albuterol sulfate contained in COMBIVENT RESPIMAT can produce a clinically significant cardiovascular effect in some patients. If cardiovascular symptoms occur, COMBIVENT RESPIMAT may need to be discontinued.
COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
COMBIVENT RESPIMAT contains ipratropium bromide and may increase intraocular pressure which may result in precipitation or worsening of narrow-angle glaucoma. Use with caution in patients with narrow-angle glaucoma.
Patients should avoid spraying the aerosol into their eyes as this may cause acute eye pain or discomfort, temporary blurring of vision, mydriasis, visual halos, or colored images in association with red eyes from conjunctival or corneal congestion. Advise patients to consult their physician immediately if any of these symptoms develop while using COMBIVENT RESPIMAT.
Ipratropium bromide also may cause urinary retention.
Caution is advised when giving COMBIVENT RESPIMAT to patients with prostatic hyperplasia, or bladder-neck obstruction.
Since dizziness and blurred vision may occur with the use of COMBIVENT RESPIMAT, caution patients about engaging in activities such as driving a vehicle or operating appliances or machinery.
Do not exceed recommended dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur. If such a reaction occurs, therapy with COMBIVENT RESPIMAT should be stopped at once and alternative treatment should be considered.
COMBIVENT RESPIMAT contains albuterol and should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines. Albuterol may produce significant hypokalemia in some patients.
In clinical trials, the most common adverse reactions reported for COMBIVENT RESPIMAT were upper respiratory tract infection, nasopharyngitis, cough, bronchitis, headache, and dyspnea.
COMBIVENT RESPIMAT may interact additively with concomitantly used anticholinergic medications. Avoid co-administration with other anticholinergic-containing drugs.
Caution is advised in co-administration of other beta-adrenergic agents, beta-receptor blocking agents, and non-potassium sparing diuretics. Extreme caution is advised with monoamine oxidase inhibitors or tricyclic antidepressants.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
CL-CBR-100026 9.6.2022
Please see full Prescribing Information, including an Instructions for Use for Combivent Respimat.